Related Experiment Video
Updated: Jun 27, 2025
07:30
Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
Published on: May 10, 2018
9.2K
SGLT-2 Inhibitors: Focus on Dapagliflozin
Zoya Siddiqui1, Somar Hadid1, William H Frishman2
1From the School of Medicine, New York Medical College, Valhalla, NY.
Cardiology in Review
|April 26, 2024
Summary
Dapagliflozin, a sodium-glucose cotransporter-2 (SGLT-2) inhibitor, effectively manages type 2 diabetes, heart failure, and chronic kidney disease. Its unique action on SGLT-2 transporters offers significant patient benefits beyond glycemic control.
Area of Science:
- Pharmacology and Therapeutics
- Cardiology
- Nephrology
Background:
- Dapagliflozin, initially for type 2 diabetes, now has expanded indications for heart failure and chronic kidney disease.
- Sodium-glucose cotransporter-2 (SGLT-2) inhibitors play a crucial role in managing cardiometabolic and renal diseases.
- The drug's efficacy extends beyond glycemic control, impacting cardiovascular and renal health.
Purpose of the Study:
- To review the expanded therapeutic applications of dapagliflozin.
- To elucidate the mechanism of action and pharmacokinetic profile of dapagliflozin.
- To compare dapagliflozin's efficacy and safety with other SGLT-2 inhibitors.
Main Methods:
- Review of clinical trial data and pharmacokinetic studies.
- Comparative analysis of dapagliflozin with other SGLT-2 inhibitors like empagliflozin and canagliflozin.
- Examination of adverse effects and contraindications.
Main Results:
- Dapagliflozin demonstrates efficacy in glycemic control without hypoglycemia risk.
- It shows potential superiority in heart failure prevention compared to some other SGLT-2 inhibitors.
- Pharmacokinetic profile shows rapid absorption, an 18-hour duration, and minimal metabolism.
Conclusions:
- Dapagliflozin is a pivotal medication for improving patient outcomes in diabetes, heart failure, and kidney disease.
- Understanding its benefits, limitations, and adverse effects is crucial for clinical decision-making.
- Its mechanism involves competitive binding to SGLT-2, preventing glucose and sodium reabsorption.
Related Concept Videos
01:23Dipeptidyl Peptidase 4 Inhibitors
181
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
181
01:24Glucagon-like Receptor Agonists
319
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
319
01:06Oral Hypoglycemic Agents: Glinides
154
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
154
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
192
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
192
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
174
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
174
01:17Oral Hypoglycemic Agents: Sulfonylureas
207
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
207